Primary and secondary prevention of Ischemic Stroke

European Neurology

Volumn 63, Issue 5, 2010, Pages 267-278

  Paciaroni, Maurizio ^a   Bogousslavsky, Julien ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Swiss Medical Network   (Switzerland)

Author keywords

Primary prevention; Stroke; Transient ischemic attack

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; CLOPIDOGREL; DABIGATRAN; DIPYRIDAMOLE; EPROSARTAN; ESTROGEN; GESTAGEN; INDAPAMIDE; NITRENDIPINE; PERINDOPRIL; PLACEBO; SIMVASTATIN; TICLOPIDINE; WARFARIN;

ALCOHOL CONSUMPTION; BLEEDING; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CAROTID ANGIOPLASTY; CAROTID ARTERY DISEASE; CAROTID ARTERY OBSTRUCTION; CAROTID ARTERY STENTING; CAROTID ENDARTERECTOMY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIETARY INTAKE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; OBESITY; OCCLUSIVE CEREBROVASCULAR DISEASE; PATENT FORAMEN OVALE; PERIPHERAL VASCULAR DISEASE; PHYSICAL ACTIVITY; PRIMARY PREVENTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; STROKE; TRANSIENT ISCHEMIC ATTACK; UNSPECIFIED SIDE EFFECT;

BRAIN ISCHEMIA; HUMANS; ISCHEMIC ATTACK, TRANSIENT; RECURRENCE; STROKE;

EID: 77950036727     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000285183     Document Type: Review

References (86)

1. Lloyd-Jones D, Adams R, Carnethon M, et al: American Heart Association: Heart disease and stroke. Statistics 2009. Update. Circulation 2009;119:e1-e161.
2. Five-year findings of the hypertension detection and follow-up program. III. Reduction in stroke incidence among persons with high blood pressure. Hypertension Detection and Follow-up Program Cooperative Group. JAMA 1982; 247: 633-638.
3. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265: 3255-3264.
4. Party MW: Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405-412.
5. Dahlöf B, Lindholm LH, Hansson L, et al: Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOPHypertension). Lancet 1991; 338: 1281-1285.
6. Verdecchia P, Staessen JA, Angeli F, et al: Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 2009; 374: 525-533.
7. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
8. HOPE Investigators: Effects of an angiotensin- converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153.
9. Dahlöf B, Devereux R, Kjeldsen S, et al: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003. (Pubitemid 34286536)
10. Sacks F, Pfeffer M, Moye L, et al: The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
11. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
12. Plehn J, Davis B, Sacks F, et al: Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The CARE Investigators. Circulation 1999; 99: 216-223.
13. MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo- controlled trial. Lancet 2002; 360: 7-22.
14. ALLHAT Collaborative Research Group: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care. JAMA 2002; 288: 2998-3007.
15. Summary of the National Cholesterol Education Program (NCEP) Adult Treatment Panel II Report. JAMA 1993; 269: 3015-3023.
16. Moghissi ES, Korytkowski MT, DiNardo MM, et al: American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatients glycemic control. Diabetes Care 2009; 32: 1119-1131.
17. Gorelick P, Sacco R, Smith D, et al: Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA 1999; 281: 1112-1120.
18. Kamachi I, Colditz G, Stampfer M, et al: Smoking cessation and decreased risk of stroke in women. JAMA 1993; 269: 232-236.
19. Wolf P, D'Agostino R, Kannel W, et al: Cigarette smoking as a risk factor for stroke: the Framingham Study. JAMA 1988; 259: 1025-1029.
20. Gorelick P: Stroke prevention: windows of opportunity and failed expectations - a discussion of modifiable cardiovascular risk factors and a prevention proposal. Neuroepidemiology 1997; 16: 163-173.
21. US Preventive Services Task Force: Guide to Clinical Prevention Services: Report to the US Preventive Services Task Force, vol XCII. Baltimore, Williams & Wilkins, 1996.
22. Mukamal KJ, Ascherio A, Mittleman MA, Conigrave KM, Camargo CA Jr, Kawachi I, Stampfer MJ, Willett WC, Rimm EB: Alcohol and risk for ischemic stroke in men: the role of drinking patterns and usual beverage. Ann Intern Med 2005; 142: 11-19.
23. Bos S, Grobbee DE, Boer JM, Verschuren WM, Beulens JW: Alcohol consumption and risk of cardiovascular disease among hypertensive women. Eur J Cardiovasc Prev Rehabil 2010; 17: 119-126.
24. NIH Consensus Development Panel: Physical activity and cardiovascular health. JAMA 1996; 276: 241-246.
25. Abbott R, Rodriguez B, Burchfiel C, Curb J: Physical activity in older middle-aged men and reduced risk of stroke: the Honolulu Heart Program. Am J Epidemiol 1994; 139: 881-893. (Pubitemid 24138391)
26. Fletcher G: Exercise in the prevention of stroke. Health Reports 1994; 6: 106-110.
27. Kiely D, Wolf P, Cupples L, et al: Physical activity and stroke risk: the Framingham Study. Am J Epidemiol 1994; 140: 608-620.
28. Haheim L, Holme I, Hjermann I, Leren P: Risk factors of stroke incidence and mortality. A 12-year follow-up of the Oslo Study. Stroke 1993; 24: 1484-1489.
29. Gillum R, Mussolino M, Ingram D: Physical activity and stroke incidence in women and men - the NHANES I Epidemiologic Followup Study. Am J Epidemiol 1996; 143: 860-869. (Pubitemid 26131093)
30. Sacco R, Gan R, Boden-Albala B, et al: Leisure- time physical activity and ischaemic stroke risk: the Northern Manhattan Stroke Study. Stroke 1998; 29: 380-387.
31. Wannamethee G, Shaper A: Physical activity and stroke in British middle aged men. BMJ 1992; 304: 597-601.
32. Manson J, Stampfer M, Willett W, et al: Physical activity and incidence of coronary heart disease and stroke in women. Circulation 1995; 91(Suppl):5.
33. Lee I, Hennekens C, Berger K, et al: Exercise and risk of stroke in male physicians. Stroke 1999; 30: 1-6.
34. Williams P: High-density lipoprotein cholesterol and other risk factors for coronary heart disease in female runners. N Engl J Med 1996; 334: 1298-1303.
35. Nygard O, Vollset S, et al: Total plasma homocysteine and cardiovascular risk profile - the Hordaland Homocysteine Study. JAMA 1995; 274: 1526-1533.
36. Gillman M, Cupples L, Posner B, et al: Protective effects of fruits and vegetables on development of stroke in men. JAMA 1995; 273: 1113-1117.
37. Gey K, Stahelin H, Eichholzer M: Poor plasma status of carotene and vitamin C is associated with higher mortality from ischaemic heart disease and stroke. Clin Invest Med 1993; 71: 3-6.
38. Khaw K, Barrett-Connor E: Dietary potassium and stroke-associated mortality. N Engl J Med 1987; 316: 235-240.
39. Benson R, Jacobs B, Boden-Albala B, et al: Vitamin E intake: a primary preventive measure in stroke. Neurology 1999; 52:A146.
40. Diaz M, Frei B, Vita J, Keaney J: Antioxidants and atherosclerotic heart disease. N Engl J Med 1997; 282: 408-416.
41. Daviglus ML, Orencia AJ, Dyer AR, et al: Dietary vitamin C, beta-carotene and 30-year risk of stroke: results from the Western Electric Study. Neuroepidemiology 1997; 16: 69-77.
42. Abbott R, Curb D, Rodriguez B, et al: Effect of dietary calcium and milk consumption on risk of thromboembolic stroke in older middle- aged men. The Honolulu Heart Study. Stroke 1996; 27: 813-818.
43. Orenica A, Daviglus M, Dyer A, et al: Fish consumption and stroke in men. 30-year findings of the Chicago Western Electric Study. Stroke 1996; 27: 204-209.
44. Morris M, Manson J, Rosner B, et al: Fish consumption and cardiovascular disease in the Physicians' Health Study: a prospective study. Am J Epidemiology 1995; 142: 166-175.
45. Ueland P, Refsum H, Brattstrom L: Plasma homocysteine and cardiovascular disease; in: Francis RB (ed): Atherosclerotic Cardiovascular Disease, Hemostatis, and Endothelial Function. New York, Marcel Dekker, 1992, pp 183-236.
46. Giles W, Croft J, Greenlund K, et al: Total homocyst(e)ine concentration and the likelihood of nonfatal stroke - results from the Third National Health and Nutrition Examination Survey, 1988-1994. Stroke 1998; 29: 2473-2477. (Pubitemid 28543992)
47. Sacco R, Roberts J, Jacobs B: Homocysteine as a risk factor for ischaemic stroke: an epidemiological story in evolution. Neuroepidemiology 1998; 17: 167-173.
48. Jacobs B, Sacco R, Lui R, et al: Low dietary intake of vitamin B6 is associated with an increased risk of ischaemic stroke. Stroke 1999; 30: 252.
49. Toole JF, Malinow MR, Chambless LE, et al: Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291: 565-575.
50. Grady D, Herrington D, Bittner V, et al: Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/ Progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 49-57. (Pubitemid 34705518)
51. Wassertheil-Smoller S, Hendrix S, Limacher M, et al: Effect of estrogen plus progestin on stroke in postmenopausal women. The Women's Health Initiative: a randomized trial. JAMA 2003; 289: 2673-2684.
52. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study: Endarterectomy for asymptomatic carotid atherosclerosis. JAMA 1995; 273: 1421-1428.
53. MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group: Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet 2004; 363: 1491-1502.
54. Connolly SJ, Ezekowitz MD, Yusuf S, et al: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
55. Connolly SJ, Pogue J, Hart RG, et al: Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360: 2066-2078.
56. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
57. PROGRESS Collaborative Group: Randomized trial of a perindopril-based blood-pressure- lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1042.
58. Beckett NS, Peters R, Fletcher AE, Staessen JA, et al: Treatment of hypertension in patients
59. Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, et al: Mortality and morbidity after stroke - eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36: 1218-1226.
60. Rashid P, Leonardi-Bee J, Bath P: Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke 2003; 34: 2741-2748.
61. Zhang H, Thijs L, Staessen JA: Blood pressure lowering for primary and secondary prevention of stroke. Hypertension 2006; 48: 187-195.
62. Bath PM, Sprigg N: Control of blood pressure after stroke. Hypertension 2006; 48. 203-204.
63. Diener HC: Preventing stroke: the PROFESS, ONTARGET, and TRASCEND trial programs. J Hypertens 2009; 27(Suppl 5):S31-S36.
64. Viscoli C, Brass L, Kernan W, et al: A clinical trial of estrogen-replacement therapy after ischaemic stroke. N Engl J Med 2001; 345: 1243-1249. (Pubitemid 34951488)
65. Fiorenza AM, Sommariva D, Branchi A: The PROSPER trial. Lancet 2003; 361: 428.
66. SPARCL Investigators: High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549-559.
67. Amarenco P, Labreuche J: Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009; 8: 453-463.
68. Sacco R: Extracranial carotid stenosis. N Engl J Med 2001; 345: 1113-1118.
69. ECST Investigators: Interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. Lancet 1991; 337: 1235-1243.
70. Dietz A, Kerkefeld J, Theron J, et al: Endovascular treatment of symptomatic carotid stenosis using stent placement: long-term follow- up of patients with a balanced surgical risk/benefit ratio. Stroke 2001; 32: 1855-1859.
71. CAVATAS Investigators: Endovascular versus surgical treatment in patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): a randomized trial. Lancet 2001; 357: 1729-1737.
72. Gurm HS, Yadav JS, Fayad P, et al: Long-term results of carotid stenting versus endarterectomy in high risk patients: the Sapphire Study. N Engl J Med 2008; 358: 1572-1579.
73. Brown MM, Ederle J, Bonati LH, et al: Safety results of the International Carotid Stenting Study. Early outcome of patients randomised between carotid stenting and endarterectomy for symptomatic carotid stenosis. European Stroke Conference Stockholm, May 2009.
74. Rothwell PM: Poor outcome after endovascular treatment of symptomatic carotid stenosis: time for a moratorium. Lancet Neurology 2009; 8: 871-873.
75. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
76. Antithrombotic Trialists' Collaboration: Aspirin in the primary and secondary prevention of vascular disease: a collaborative meta- analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-1860.
77. Gorelick P, Richardson D, Kelly M, et al: Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA 2003; 289: 2947-2957.
78. Diener H, Cunha L, Forbes C, et al: European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.
79. Halkes PH, van Gijn J, Kappelle LJ, et al: Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367: 1665-1673.
80. CAPRIE Committee: A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
81. Diener HC, Bogousslavsky J, Brass LM et al, MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-337.
82. Sacco RL, Diener HC, Yusuf S, et al: Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359: 1238-1251.
83. Mohr J, Thompson J, Lazar R, et al: A comparison of warfarin and aspirin for the prevention of recurrent ischaemic stroke. N Engl J Med 2001; 345: 1444-1451.
84. Chimowitz MI, Lynn, MJ, Howlett-Smith H, et al: Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352: 1305-1316.
85. Toole JF, Malinow MR, Chambless LE, et al: Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291: 565-575.
86. Homma S, Sacco R, Di Tullio M, et al: Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation 2002; 105: 2625-2631